A tiny fish-oil drug rival trash talks Amarin, but there's still much to prove - STAT

A tiny fish-oil drug rival trash talks Amarin, but there's still much to prove - STAT

Inside STAT: A fish-oil drug rival trash talks Amarin

(ADOBE)

Matinas BioPharma shelved its work on a prescription fish oil pill three years ago. Then, last month, the biotech company Amarin announcedthat its own proprietary fish oil drug, Vascepa, significantly cut the risk of cardiovascular problems. Amarin’s stock price soared — and Matinas started resurrecting its own drug. “We’re so thrilled for Amarin because they took advantage of the opportunity to create a new class of drug where they have the opportunity to treat 64 million patients per year. And we stand just behind them with a better drug,” Matinas CEO Jerry Jabbour said at a recent conference. But getting a cut of the success is easier said than done, STAT’s Adam Feuerstein says. More here.